Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS

CAMBRIDGE, Mass.--(BUSINESS WIRE) February 2, 2022 -- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials